<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0011009'>Acute</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) secondary to <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) is characterized by poor prognosis, namely in older patients </plain></SENT>
<SENT sid="1" pm="."><plain>The combination of fludarabine (F) with <z:chebi fb="0" ids="28680">cytarabine</z:chebi> (ARA-C) ± G-CSF was proven as effective in patients with poor risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>The efficacy and toxicity of a regimen including F + ARA-C as sequential continuous infusion (CI-FLA) in 64 untreated patients aged &gt;60 years, in which <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> arose after a previous <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, was investigated </plain></SENT>
<SENT sid="3" pm="."><plain>Median age was 67 years (61-81) </plain></SENT>
<SENT sid="4" pm="."><plain>In patients achieving CR, an additional course, followed by G-CSF to mobilize CD34+ cells and subsequent autologous stem cell transplantation (ASCT) were programmed </plain></SENT>
<SENT sid="5" pm="."><plain>Overall, 43 patients (67%) achieved complete remission (CR) </plain></SENT>
<SENT sid="6" pm="."><plain>There were 10 induction <z:hpo ids='HP_0011420'>deaths</z:hpo> (16%), while 11 patients (17%) were refractory to induction treatment </plain></SENT>
<SENT sid="7" pm="."><plain>Thirty-four patients (79% of remitters) were eligible for the consolidation and 30 were monitorized for the mobilization of CD34+ cells, collection being successful in 20 of them (67%) </plain></SENT>
<SENT sid="8" pm="."><plain>Median number of CD34+ cells/kg collected was 6.8 × 10E6 </plain></SENT>
<SENT sid="9" pm="."><plain>Thirteen patients (20% of the whole population) received ASCT </plain></SENT>
<SENT sid="10" pm="."><plain>Median disease free survival (DFS) and overall survival (OS) were 10 and 9 months, respectively </plain></SENT>
<SENT sid="11" pm="."><plain>Survival at 5 years is projected to 15% </plain></SENT>
<SENT sid="12" pm="."><plain>The only parameter significantly related to either DFS duration or OS duration was unfavourable cytogenetics, which did significantly influence also CR achievement </plain></SENT>
<SENT sid="13" pm="."><plain>CI-FLA is effective in elderly patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> secondary to previously diagnosed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="14" pm="."><plain>Best results are achievable in the subgroup of patients with diploid karyotype </plain></SENT>
</text></document>